PRISM0CAL 6.449 G / 1000 ML
SODIUM CHLORIDE : 6.449 G / 1000 ML LACTIC ACID : 0.284 G / 1000 ML MAGNESIUM CHLORIDE : 0.108 G / 1000 ML SODIUM BICARBONATE : 58.8 G / 1000 ML · DIN 02274876 · VANTIVE ULC
Health Canada status: MARKETED
What is PRISM0CAL?
PRISM0CAL 6.449 G / 1000 ML contains SODIUM CHLORIDE : 6.449 G / 1000 ML LACTIC ACID : 0.284 G / 1000 ML MAGNESIUM CHLORIDE : 0.108 G / 1000 ML SODIUM BICARBONATE : 58.8 G / 1000 ML. It is listed in the Health Canada Drug Product Database under DIN 02274876, held by VANTIVE ULC, supplied as SOLUTION for INTRAVENOUS ; HAEMODIALYSIS administration. Health Canada currently lists it as marketed, status dated 18-Apr-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PRISM0CAL used for?
Treatment of acute renal failure (hemofiltration/hemodiafiltration/hemodialysis) in CRRT; patients with tendency to hyperkalaemia/hypercalcemia; drug poisoning with dialysable substances.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02274876 |
|---|---|
| Brand name | PRISM0CAL |
| Generic / active ingredient | SODIUM CHLORIDE : 6.449 G / 1000 ML LACTIC ACID : 0.284 G / 1000 ML MAGNESIUM CHLORIDE : 0.108 G / 1000 ML SODIUM BICARBONATE : 58.8 G / 1000 ML |
| Manufacturer | VANTIVE ULC |
| Strength | 6.449 G / 1000 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS ; HAEMODIALYSIS |
| Schedule | Ethical |
| ATC code | B05ZA HEMODIALYTICS, CONCENTRATES |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 18-Apr-2024 |
How is it administered?
Administered via hemofilter or hemodiafilter. Adult flow rates: 500-3000 mL/h (replacement) or 500-2500 mL/h (dialysate). Must mix compartments A and B before use.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 4°C and 30°C. Do not refrigerate. Protect from freezing. Reconstituted solution stable for 24 hours at 22°C.
How is it supplied?
Two-compartment bag (5000 mL total: 250 mL small, 4750 mL large). Pack size: 2 x 5000 mL in a box.
Contraindications
Hypokalaemia, metabolic alkalosis, hypocalcaemia, and known hypersensitivity to the product.
Warnings and precautions
Potassium-free and calcium-free (risk of hypocalcaemia/hypokalaemia); dextrose-free (risk of hypoglycemia); monitor hemodynamic status, fluid, electrolyte, and acid-base balance.
What can be used instead?
Other Canadian products sharing ATC code B05ZA HEMODIALYTICS, CONCENTRATES. 117 of 588 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACID CONCENTRATE 2156 | 10.1 G | SOLUTION | VANTIVE ULC | MARKETED | DIN 02239491 |
| ACID CONCENTRATE 2182 | 262.98 G | SOLUTION | VANTIVE ULC | MARKETED | DIN 02210835 |
| ACID CONCENTRATE A1221 | 3.35 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254344 |
| ACID CONCENTRATE A1222 | 263 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254336 |
| ACID CONCENTRATE A1223 | 9.92 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254328 |
| ACID CONCENTRATE A1224 | 263 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254301 |
| ACID CONCENTRATE A1225 | 263.0 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254298 |
| ACID CONCENTRATE A1226 | 49.5 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254255 |
| ACID CONCENTRATE A1227 | 8.27 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254247 |
| ACID CONCENTRATE A1228 | 49.5 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02533774 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.